Immune System Key Ltd.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.
LATEST NEWS
IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer
Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.
New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum
Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
Phase II update – A second patient (92 years old) had a strong reduction in blasts in the bone marrow
No side effects were recorded
Update from AML human trial in Miami
Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:
8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.
In cohort 1 (dose=6mg/m^2) three patients were enrolled.
The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third patient was using a wheelchair when enrolled to the trial. This patient is now alive for 12 months, walking free and with stable disease.
In cohort 2 (dose=96mg/m^2) two patients were enrolled.
The first patient was using a wheelchair when enrolled to the trial. This patient is now 10 months into the trial doing gymnastics and feels great.
The cancer cells in her bone marrow and blood
